# Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

> **NCT01365507** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 276 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** insulin degludec/insulin aspart

## Key facts

- **NCT ID:** NCT01365507
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 276 (ACTUAL)
- **Last updated:** 2017-03-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01365507

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01365507, "Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01365507. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*